Contact tolerance.
Contact tolerance describes an immunological state which is caused by ordinary contact allergens painted in doses too low to sensitize, either once or repeatedly, onto healthy intact skin. The tolerance state accomplished by this means in BALB/c and C57BI/6 mice was found to be mediated by hapten-specific T cells that adoptively transferred tolerance to naive recipients. Furthermore, these cells were shown to be sensitive to cyclophosphamide, to express the Lyt2+ (CD8) phenotype, and to produce, upon restimulation in vitro, predominantly anti-inflammatory cytokines such as IL-4, IL-5 and IL-10. These data indicate that contact tolerance of the low zone type is actively mediated by Th2-like CD8 T cells rather than arising as a consequence of clonal anergy. The induction of contact tolerance appeared to be strictly dose-dependent. As opposed to sensitizing doses of allergen, subsensitizing doses did not involve epidermal Langerhans cells discernibly. This was suggested by their normal ultrastructure, their unaffected adenosine triphosphatase system, the inefficacy of functional blocking and excision experiments. Both radiolabeled and fluorescent contact sensitizers were observed to readily enter the bloodstream, thereby being dispersed throughout the body. Presumably, contact tolerance is induced systemically rather than locally. The presence of hapten-specific tolerance can only be uncovered through a subsequent attempt to sensitize. If the attained sensitization turns out to be significantly lower than that of immunologically naive controls, and if sensitization to chemically unrelated sensitizers is not impaired, hapten-specific tolerance does exist. Thus, contact tolerance is a result obtained from experimental sensitization in animals. Nonetheless, it is assumed to occur also in humans, although it is not demonstrable unless different proofs of existence become available.
Steinbrink
K
K
Institute of Experimental Dermatology, University of Münster, Germany.
Pior
J
J
Vogl
T
T
Sorg
C
C
Macher
E
E
D000287:Administration, Topical; D000485:Allergens / Q000276:immunology*; D000818:Animals; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology; D002478:Cells, Cultured; D017449:Dermatitis, Allergic Contact / Q000276:immunology*; D004306:Dose-Response Relationship, Immunologic; D016650:Fluorescein-5-isothiocyanate / Q000008:administration & dosage / Q000494:pharmacology; D006241:Haptens / Q000276:immunology; D007108:Immune Tolerance / Q000276:immunology*; D007165:Immunosuppression Therapy; D007378:Interleukins / Q000378:metabolism; D007801:Langerhans Cells / Q000187:drug effects / Q000276:immunology; D008198:Lymph Nodes / Q000166:cytology / Q000378:metabolism; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D010081:Oxazolone / Q000008:administration & dosage / Q000494:pharmacology; D010853:Picryl Chloride / Q000008:administration & dosage / Q000494:pharmacology
D000485:Allergens; D006241:Haptens; D007378:Interleukins; D010081:Oxazolone; D016650:Fluorescein-5-isothiocyanate; D010853:Picryl Chloride